Sentiment-Signal
15,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Unternehmen & Branche
| Name | Kymera Therapeutics, Inc. |
|---|---|
| Ticker | KYMR |
| CIK | 0001815442 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 6,67 Mrd. USD |
| Beta | 2,29 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 39,211,000 | -311,351,000 | -3.69 | 1,742,812,000 | 1,579,664,000 |
| 2025-09-30 | 10-Q | 2,764,000 | -82,175,000 | -0.94 | 1,102,044,000 | 946,258,000 |
| 2025-06-30 | 10-Q | 11,476,000 | -76,614,000 | -0.95 | 1,131,068,000 | 971,480,000 |
| 2025-03-31 | 10-Q | 22,100,000 | -65,581,000 | -0.82 | 918,312,000 | 786,233,000 |
| 2024-12-31 | 10-K | 47,072,000 | -223,858,000 | -2.98 | 978,035,000 | 835,619,000 |
| 2024-09-30 | 10-Q | 3,741,000 | -62,487,000 | -0.82 | 1,034,842,000 | 892,930,000 |
| 2024-06-30 | 10-Q | 25,650,000 | -42,062,000 | -0.58 | 826,021,000 | 684,924,000 |
| 2024-03-31 | 10-Q | 10,287,000 | -48,557,000 | -0.69 | 868,251,000 | 711,203,000 |
| 2023-12-31 | 10-K | 78,592,000 | -146,962,000 | -2.52 | 575,759,000 | 394,971,000 |
| 2023-09-30 | 10-Q | 4,728,000 | -52,867,000 | -0.90 | 552,378,000 | 395,535,000 |
| 2023-06-30 | 10-Q | 16,513,000 | -38,799,000 | -0.67 | 581,945,000 | 435,428,000 |
| 2023-03-31 | 10-Q | 9,466,000 | -40,928,000 | -0.70 | 613,905,000 | 462,005,000 |
| 2022-12-31 | 10-K | 46,826,000 | -154,808,000 | -2.87 | 603,134,000 | 490,151,000 |
| 2022-09-30 | 10-Q | 9,551,000 | -43,002,000 | -0.79 | 638,472,000 | 512,885,000 |
| 2022-06-30 | 10-Q | 11,514,000 | -40,257,000 | -0.78 | 523,421,000 | 397,951,000 |
| 2022-03-31 | 10-Q | 9,622,000 | -36,684,000 | -0.71 | 563,060,000 | 428,720,000 |
| 2021-12-31 | 10-K | 72,832,000 | -100,217,000 | -2.09 | 605,905,000 | 459,638,000 |
| 2021-09-30 | 10-Q | 20,336,000 | -28,582,000 | -0.56 | 642,453,000 | 483,135,000 |
| 2021-06-30 | 10-Q | 18,519,000 | -24,660,000 | -0.55 | 434,386,000 | 258,104,000 |
| 2021-03-31 | 10-Q | 18,702,000 | -13,075,000 | 464,552,000 | 275,247,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -936 | 82.45 | -77,173.20 | -3,0% | |
| 2026-04-29 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -12,059 | 81.70 | -985,220.30 | -38,0% | |
| 2026-04-29 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -17,005 | 80.74 | -1,372,983.70 | -53,0% | |
| 2026-04-15 | Booth Bruce | Director | Open Market Sale | -2,750 | 90.10 | -247,775.00 | -9,6% | |
| 2026-04-15 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -1,300 | 90.00 | -117,000.00 | -4,5% | |
| 2026-04-15 | Booth Bruce | Director | Open Market Sale | -2,200 | 89.95 | -197,890.00 | -7,6% | |
| 2026-04-15 | Booth Bruce | Director | Open Market Sale | -385 | 90.10 | -34,688.50 | -1,3% | |
| 2026-04-14 | Booth Bruce | Director | Open Market Sale | -4,159 | 89.97 | -374,185.23 | -14,4% | |
| 2026-04-14 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -5,251 | 90.00 | -472,598.40 | -18,2% | |
| 2026-04-14 | Goodman Noah | Officer, Chief Business Officer | Open Market Sale | -1,347 | 90.00 | -121,230.00 | -4,7% | |
| 2026-04-10 | Goodman Noah | Officer, Chief Business Officer | Open Market Sale | -2,000 | 87.35 | -174,700.00 | -6,7% | |
| 2026-04-09 | Goodman Noah | Officer, Chief Business Officer | Open Market Sale | -2,670 | 87.11 | -232,586.10 | -9,0% | |
| 2026-04-09 | Goodman Noah | Officer, Chief Business Officer | Open Market Sale | -3,094 | 86.62 | -267,996.09 | -10,3% | |
| 2026-04-09 | Goodman Noah | Officer, Chief Business Officer | Open Market Sale | -2,500 | 89.00 | -222,500.00 | -8,6% | |
| 2026-04-01 | Ridloff Elena | Director | Open Market Sale | -1,200 | 86.05 | -103,260.00 | -4,0% | |
| 2026-04-01 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -13,540 | 85.41 | -1,156,510.98 | -44,6% | |
| 2026-04-01 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -1,100 | 86.05 | -94,655.00 | -3,7% | |
| 2026-04-01 | Ridloff Elena | Director | Open Market Sale | -3,400 | 85.19 | -289,661.64 | -11,2% | |
| 2026-03-31 | Ridloff Elena | Director | Open Market Sale | -7,400 | 85.37 | -631,738.74 | -24,4% | |
| 2026-03-31 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -7,600 | 85.38 | -648,881.92 | -25,0% | |
| 2026-03-20 | Esposito Pamela | Director | Open Market Sale | -700 | 77.71 | -54,397.77 | -2,1% | |
| 2026-03-20 | Esposito Pamela | Director | Open Market Sale | -1,200 | 79.94 | -95,933.04 | -3,7% | |
| 2026-03-20 | Esposito Pamela | Director | Open Market Sale | -600 | 79.24 | -47,546.34 | -1,8% | |
| 2026-03-11 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -11,111 | 83.72 | -930,207.36 | -35,9% | |
| 2026-03-11 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -12,882 | 83.10 | -1,070,510.95 | -41,3% | |
| 2026-03-11 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -1,765 | 82.13 | -144,955.04 | -5,6% | |
| 2026-03-04 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -2,017 | 85.04 | -171,518.42 | -6,6% | |
| 2026-03-04 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -2,519 | 85.04 | -214,206.69 | -8,3% | |
| 2026-03-04 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -1,437 | 85.78 | -123,266.87 | -4,8% | |
| 2026-03-04 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -492 | 84.00 | -41,326.28 | -1,6% | |
| 2026-03-04 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -447 | 86.62 | -38,721.24 | -1,5% | |
| 2026-03-04 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -2,519 | 85.04 | -214,206.69 | -8,3% | |
| 2026-03-04 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -1,437 | 85.78 | -123,266.87 | -4,8% | |
| 2026-03-04 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -492 | 84.00 | -41,326.28 | -1,6% | |
| 2026-03-04 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -447 | 86.62 | -38,721.24 | -1,5% | |
| 2026-03-04 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -1,150 | 85.78 | -98,647.81 | -3,8% | |
| 2026-03-04 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -394 | 84.00 | -33,094.62 | -1,3% | |
| 2026-03-04 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -358 | 86.62 | -31,011.64 | -1,2% | |
| 2026-03-02 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -3,048 | 89.66 | -273,275.76 | -10,5% | |
| 2026-03-02 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -1,510 | 87.75 | -132,503.86 | -5,1% | |
| 2026-03-02 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -1,055 | 88.50 | -93,367.92 | -3,6% | |
| 2026-03-02 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -549 | 87.75 | -48,175.24 | -1,9% | |
| 2026-03-02 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -383 | 88.50 | -33,895.65 | -1,3% | |
| 2026-03-02 | Booth Bruce | Director | Open Market Sale | -71,814 | 90.13 | -6,472,595.82 | -249,6% | |
| 2026-03-02 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -4,113 | 89.66 | -368,760.89 | -14,2% | |
| 2026-03-02 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -2,039 | 87.75 | -178,924.09 | -6,9% | |
| 2026-03-02 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -1,424 | 88.50 | -126,024.57 | -4,9% | |
| 2026-03-02 | Booth Bruce | Director | Open Market Sale | -10,052 | 90.13 | -905,986.76 | -34,9% | |
| 2026-03-02 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -1,107 | 89.66 | -99,250.74 | -3,8% | |
| 2026-02-25 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -3,293 | 91.76 | -302,165.68 | -11,7% | |
| 2026-02-25 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -19,764 | 89.78 | -1,774,411.92 | -68,4% | |
| 2026-02-25 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -1,501 | 92.81 | -139,307.81 | -5,4% | |
| 2026-02-25 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -8 | 93.49 | -747.92 | 0,0% | |
| 2026-02-25 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -5,434 | 90.39 | -491,179.26 | -18,9% | |
| 2026-02-20 | Esposito Pamela | Director | Open Market Sale | -600 | 88.10 | -52,860.00 | -2,0% | |
| 2026-02-20 | Esposito Pamela | Director | Open Market Sale | -1,900 | 87.06 | -165,410.01 | -6,4% | |
| 2026-01-20 | Esposito Pamela | Director | Open Market Sale | -4,900 | 67.99 | -333,145.12 | -12,8% | |
| 2026-01-20 | Esposito Pamela | Director | Open Market Sale | -200 | 68.52 | -13,704.00 | -0,5% | |
| 2026-01-20 | Esposito Pamela | Director | Open Market Sale | -400 | 66.68 | -26,672.00 | -1,0% | |
| 2025-12-31 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -23,986 | 77.95 | -1,869,727.89 | -72,1% | |
| 2025-12-31 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -6,014 | 78.52 | -472,211.46 | -18,2% | |
| 2025-12-17 | Esposito Pamela | Director | Open Market Sale | -1,000 | 84.07 | -84,070.00 | -3,2% | |
| 2025-12-17 | Esposito Pamela | Director | Open Market Sale | -14,505 | 81.56 | -1,182,984.29 | -45,6% | |
| 2025-12-17 | Esposito Pamela | Director | Open Market Sale | -7,959 | 82.34 | -655,361.57 | -25,3% | |
| 2025-12-17 | Esposito Pamela | Director | Open Market Sale | -4,099 | 83.45 | -342,064.42 | -13,2% | |
| 2025-12-12 | Booth Bruce | Director | Open Market Sale | -570 | 91.04 | -51,892.80 | -2,0% | |
| 2025-12-12 | Booth Bruce | Director | Open Market Sale | -108 | 91.04 | -9,832.32 | -0,4% | |
| 2025-12-11 | BAKER BROS. ADVISORS LP | Director, 10% Owner | Open Market Purchase | 167,192 | 86.00 | 14,378,512.00 | +554,5% | |
| 2025-12-11 | Booth Bruce | Director | Open Market Sale | -5,125 | 91.23 | -467,553.75 | -18,0% | |
| 2025-12-11 | Booth Bruce | Director | Open Market Sale | -976 | 91.23 | -89,040.48 | -3,4% | |
| 2025-12-11 | BAKER BROS. ADVISORS LP | Director, 10% Owner | Open Market Purchase | 1,838,621 | 86.00 | 158,121,406.00 | +6098,4% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -47,349 | 92.41 | -4,375,521.09 | -168,8% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -31,459 | 88.64 | -2,788,525.76 | -107,5% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -17,825 | 89.25 | -1,590,881.25 | -61,4% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -16,338 | 93.20 | -1,522,701.60 | -58,7% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -10,545 | 90.14 | -950,526.30 | -36,7% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -9,060 | 92.41 | -837,234.60 | -32,3% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -5,979 | 88.64 | -529,978.56 | -20,4% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -3,391 | 89.25 | -302,646.75 | -11,7% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -2,001 | 90.14 | -180,370.14 | -7,0% | |
| 2025-12-10 | Booth Bruce | Director | Open Market Sale | -85,862 | 93.20 | -8,002,338.40 | -308,6% | |
| 2025-12-08 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -3,929 | 89.43 | -351,356.33 | -13,6% | |
| 2025-12-08 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 89.17 | -8,917,000.00 | -343,9% | |
| 2025-12-08 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -18,357 | 88.02 | -1,615,810.68 | -62,3% | |
| 2025-12-08 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -13,759 | 87.37 | -1,202,138.96 | -46,4% | |
| 2025-12-08 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -8,562 | 90.12 | -771,629.70 | -29,8% | |
| 2025-12-08 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -3,300 | 91.46 | -301,830.87 | -11,6% | |
| 2025-12-08 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -1,400 | 92.19 | -129,066.00 | -5,0% | |
| 2025-12-08 | Albers Jeffrey W. | Director | Open Market Sale | -2,748 | 89.32 | -245,459.60 | -9,5% | |
| 2025-12-08 | Albers Jeffrey W. | Director | Open Market Sale | -2,252 | 90.30 | -203,363.48 | -7,8% | |
| 2025-10-29 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -1,862 | 59.72 | -111,203.30 | -4,3% | |
| 2025-10-29 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -24,511 | 61.02 | -1,495,626.90 | -57,7% | |
| 2025-10-29 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -3,627 | 61.46 | -222,906.72 | -8,6% | |
| 2025-10-15 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -6,453 | 63.09 | -407,099.12 | -15,7% | |
| 2025-10-15 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -29,264 | 60.37 | -1,766,667.68 | -68,1% | |
| 2025-10-15 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -14,896 | 62.72 | -934,326.28 | -36,0% | |
| 2025-10-15 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -8,963 | 61.49 | -551,160.86 | -21,3% | |
| 2025-10-13 | Gollob Jared | Officer, Chief Medical Officer | Open Market Sale | -3,114 | 60.00 | -186,840.00 | -7,2% | |
| 2025-10-13 | Albers Jeffrey W. | Director | Open Market Sale | -5,000 | 59.19 | -295,949.00 | -11,4% | |
| 2025-09-17 | Jacobs Bruce N. | Officer, Chief Financial Officer | Open Market Sale | -79,220 | 50.00 | -3,961,380.26 | -152,8% | |
| 2025-09-16 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -30,000 | 49.00 | -1,470,000.00 | -56,7% | |
| 2025-06-30 | BAKER BROS. ADVISORS LP | Director | Open Market Purchase | 55,191 | 44.00 | 2,428,404.00 | +93,7% | |
| 2025-06-30 | BVF PARTNERS L P/IL | Director | Open Market Purchase | 142,604 | 44.00 | 6,274,576.00 | +242,0% | |
| 2025-06-30 | BVF PARTNERS L P/IL | Director | Open Market Purchase | 115,783 | 44.00 | 5,094,452.00 | +196,5% | |
| 2025-06-30 | BVF PARTNERS L P/IL | Director | Open Market Purchase | 58,780 | 44.00 | 2,586,320.00 | +99,7% | |
| 2025-06-30 | BAKER BROS. ADVISORS LP | Director | Open Market Purchase | 600,309 | 44.00 | 26,413,596.00 | +1018,7% | |
| 2025-06-11 | Ridloff Elena | Director | Open Market Sale | -4,500 | 50.00 | -225,000.00 | -8,7% | |
| 2025-06-03 | Ridloff Elena | Director | Open Market Sale | -7,200 | 45.50 | -327,600.00 | -12,6% | |
| 2025-06-03 | Mainolfi Nello | Director, Officer, Chief Executive Officer | Open Market Sale | -30,000 | 49.00 | -1,470,000.00 | -56,7% | |
| 2025-06-03 | Ridloff Elena | Director | Open Market Sale | -4,800 | 47.00 | -225,600.00 | -8,7% | |
| 2025-06-03 | Esposito Pamela | Director | Open Market Sale | -5,000 | 49.04 | -245,185.50 | -9,5% | |
| 2025-06-03 | Albers Jeffrey W. | Director | Open Market Sale | -6,349 | 49.00 | -311,101.00 | -12,0% | |
| 2025-05-23 | Chadwick Jeremy G | Officer, Chief Operating Officer | Open Market Sale | -2,575 | 29.30 | -75,435.66 | -2,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.